Pandey Vivek, Madi Sandesh, Gupta Pawan
Sports Injury and Arthroscopy Division, Orthopaedics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.
Stempeutics Research Pvt. Ltd, Manipal Hospital, Whitefield, Banaglore, 560048, India.
J Clin Orthop Trauma. 2022 Feb 9;26:101804. doi: 10.1016/j.jcot.2022.101804. eCollection 2022 Mar.
Mesenchymal stromal cells (MSCs) express a wide range of properties anticipated to be beneficial for treating genetic, mechanical, and age-related degeneration in diseases such as osteoarthritis (OA). Although contemporary conservative management of OA is successful in many patients with mild-moderate OA, it often fails to improve symptoms in many patients who are not a candidate for any surgical management. Further, existing conservative treatment strategies do not prevent the progression of the disease and therefore fail to provide a long-term pain-free life. On the other hand, tremendous progress has been taking place in the exciting field of regenerative medicine involving MSCs (autologous and allogeneic), with promising translation taking place from basic science to the bedside. In this review, we comprehensively discuss the potential role of MSCs in treating OA, both autologous and off-the-shelf, allogeneic stem cells. Further, newer therapies are in the offing to treat OA, such as exosomes and growth factors.
Int J Mol Sci. 2024-12-25
Front Bioeng Biotechnol. 2023-5-9
Front Bioeng Biotechnol. 2022-7-22
Stem Cell Res Ther. 2021-10-18
Stem Cells Int. 2021-2-12